Alfuzosin fails to reduce symptoms in chronic prostatitis
AstraZeneca and MAP Pharmaceuticals, Inc. have announced an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals’ proprietary nebulized formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for pediatric asthma and is currently in Phase III clinical development. UDB has the potential to be nebulized
Full Post: AstraZeneca and MAP Pharmaceuticals announce collaboration on Unit Dose Budesonide
Alfuzosin, a drug commonly prescribed for men with chronic prostatitis, a painful disorder of the prostate and surrounding pelvic area, failed to significantly reduce symptoms in recently diagnosed men who had not been previously treated with this drug, according to a clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH).
The study is to be published in the New England Journal of Medicine .
“Although these results are disappointing, it is just as important to find out what doesn’t work as it is to know what does,” said NIDDK Director Griffin P. Rodgers, M.D. “We have conclusively shown that a drug commonly prescribed for men with chronic prostatitis did not significantly reduce symptoms compared to a placebo.”
Chronic prostatitis, which has no known cause and no uniformly effective therapy, is the most common type of prostatitis seen by physicians. Men with this condition experience pain in the genital and urinary tract areas, lower urinary tract symptoms such as pain in the bladder area and during urination, and sexual problems that can severely affect their quality of life. Population-based surveys estimate that 6 percent to 12 percent of men have prostatitis-like symptoms.
A total of 272 men diagnosed with chronic prostatitis were randomly assigned to take either alfuzosin or an identical-looking placebo. Of these, 233 men completed the trial. The primary outcome was a decrease (improvement) in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) of at least four points over 12 weeks of treatment. A 4-point decrease in the NIH-CPSI score has been shown to be the minimal clinically significant difference perceived by patients as beneficial. The index measures the three most important symptoms of chronic prostatitis - pain, problems with urination, and negative effects on quality of life.
The rates of response of the NIH-CPSI in the alfuzosin group and placebo groups were the same - 49.4 percent. In addition, there were no significant differences between the two groups in the changes over time in most of the secondary outcomes, including the total NIH-CPSI score and a global response assessment.
Despite a lack of rigorous evidence supporting the use of antibiotics or alpha blockers for chronic prostatitis, more than three-fourths of primary care physicians often prescribe antibiotics and more than one-half regularly prescribe alpha blockers such as alfuzosin for the condition, according to a recent survey supported by NIDDK. Alpha blockers are a class of drugs that relax the smooth muscle of the bladder and prostate.
“Our findings do not support the use of alpha blockers for treating new cases of chronic prostatitis,” said J. Curtis Nickel, M.D., of Queen’s University in Kingston, Ontario, Canada, and lead author of the study. “But the results of our study will inform future clinical trials of alpha blockers and other potential therapies.”
In the December issue of European Urology Dr. Curtis Nickel and associates report on the evidence of a relationship between prostate inflammation and lower urinary tract symptoms (LUTS) in men enrolled in the REDUCE trial. The REDUCE (Reduction by DUtasteride of prostate Cancer Events) trial is a 4-year, phase-III placebo-controlled study that evaluates whether the
Full Post: Link between prostate inflammation and lower urinary tract symptoms
The Great American Smokeout is this Thursday, and the American Urological Association (AUA) gives smokers another good reason to quit: Smoking causes bladder cancer. Only about 33 percent of people know that smoking is a leading risk factor for the disease, according to a new study published in The Journal of Urology, the official journal
Full Post: Smoking causes bladder cancer
Nymox Pharmaceutical Corporation has announced that the Company’s latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion. The Company anticipates the reporting of final results and statistical analysis for the study within the next 2-3 weeks. The new study concerns assessment of the
Full Post: Nymox nears completion of benign prostatic hyperplasia drug trial
Dysuria is painful urination. It is a condition wherein you experience discomfort, burning sensation, and pain while passing urine. The pain occurs in urethra and perineum (area around the genitals). Dysuria isn’t a disease. It is a symptom of diseases. It prevails in both the sexes but, women experience dysuria more as compared to men. The causes
Full Post: Home Remedies for Dysuria
A study published in the December issue of Cancer Prevention Research, a journal of the American Association for Cancer Research, suggests that selenium, a trace mineral found in grains, nuts and meats, may aid in the prevention of high-risk bladder cancer. Researchers from Dartmouth Medical School compared selenium levels in 767 individuals newly diagnosed with
Full Post: Selenium may protect from high risk-bladder cancer